June 28 (Reuters) - Eli Lilly & Co and Boehringer
Ingelheim should be allowed to claim that their diabetes drug
Jardiance cuts the risk of cardiovascular death, an advisory
panel to the U.S. Food and Drug Administration concluded on
Tuesday.
Read more
No comments:
Post a Comment